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Myocardial perfusion abnormalities detected during either exer-
cise or pharmacological stress are due to differential blood flow
between normal and stenotic arteries. The determination of these
disparities is dependent on the ability of different tracers to reflect
the changes in increased blood flow produced by the stressors.
All myocardial perfusion imaging agents available for clinical use
have shown a linear relationship with up to approximately twofold
higher than baseline. Beyond this level, there appears to be
a decrease in the uptake of most agents in relation to blood flow.
The plateau effect of various tracers has been demonstrated to be
different. It should be considered that exercise is typically accom-
panied by two to threefold increase in myocardial blood flow that
typically increases three to eightfold (compared with resting blood
flow) in response to all pharmacological agents. Myocardial per-
fusion tracers available for clinical use include thallium-201
and technetium-99m (Tc-99m) labelled agents: sestamibi and
tetrofosmin. The relationship between blood flow and these trac-
ers has been widely studied. Blood flow and thallium activity shows
a linear relationship to at least 3 ml/min/gm. However, at approx-
imately 3 ml/min/gm, there appears to be a plateau effect such
that, despite increases in blood flow, thallium activity does not
change. The extraction fraction of sestamibi is less than thallium.
Data from animal studies demonstrate a linear relationship of ses-
tamibi uptake to approximately 2 ml/min/gm. Above this level,
uptake is not linear with increasing flow. Similar data are emerg-
ing for tetrofosmin but this tracer demonstrates a plateau during
stress at a blood flow level lower than that of sestamibi. Thus,
thallium as well as sestamibi and tetrofosmin exhibits a plateau
effect that is generally above the blood flow range of exercise or
most pharmacological stress. The Tc-99m labeled tracer with the
best extraction fraction (higher than thallium) is teboroxime, that
has shown a linear correlation within the range of pharmacologi-
cal stress. However, the rapid clearance of this tracer from the
myocardium has made this agent difficult to use clinically. All these
tracers have different kinetic characteristics that must be consid-
ered to maximize their clinical applications for stress imaging.
Moreover, it should be also considered that in clinical imaging
ideal conditions do not always exist.
Despite the differences in tracer kinetic among these tracers,
comparative studies involving thallium and Tc-99m labeled agents
have failed to show significant differences. Several clinical stud-
ies have documented the clinical impact of thallium imaging in
the detection of patients with coronary artery disease. In particu-
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Nuclear medicine imaging in cardiology
During the past two decades the clinical role of nuclear med-
icine procedures in cardiology has evolved significantly. At the
beginning, the diagnostic role of nuclear medicine in detecting
myocardial ischemia in patients with suspected coronary artery
disease has been emphasized. Subsequently, cardiac radionu-
clide imaging has made significant advances in the determina-
tion of prognosis in patients with ischemic heart disease, preop-
erative risk assessment for patients undergoing non cardiac sur-
gery and assessment of the efficacy of revascularization in pa-
tients undergoing coronary artery bypass surgery or intervention-
al procedures. More recently, particularly attention has been fo-
cused on the ability of nuclear cardiology to characterize myocar-
dial tissue and to assess myocardial viability in patients with is-
chemic left ventricular (LV) dysfunction.
Diagnosis of coronary artery disease
Myocardial perfusion imaging with exercise or pharmacolog-
ical stress testing is an accepted technique for the detection and
localization of coronary artery disease [1, 2]. During exercise or
pharmacological stress, the vasodilating capacity of microcircu-
lation is limited and obstruction in the epicardial coronary arteries
become physiologically important, providing a mechanism for the
noninvasive diagnosis of obstructive coronary artery disease.
60
Nuclear Medicine Review 2003, Vol. 6, No. 1
www.nmr.viamedica.pl
Lecture
lar, the sensitivity of single-photon emission computed tomogra-
phy (SPECT) thallium imaging has been reported to be approxi-
mately 90% with a relative low specificity, ranging from 60% to 70%.
Since their introduction, sestamibi and tetrofosmin have been
compared to thallium as the gold standard in the identification of
patients with coronary artery disease. The reported average sen-
sitivity and specificity of sestamibi and tetrofosmin in the identifi-
cation of coronary artery disease were very similar to those ob-
tained with thallium imaging. However, some data reported that
sestamibi and tetrofosmin might underestimate the total extent of
myocardial ischemia as compared to thallium imaging in patients
with coronary artery disease [3]. On the other hand, significant
differences regarding the image quality has been reported in all
comparative studies performed. In particular, images obtained
using sestamibi or tetrofosmin were of superior quality than those
obtained with thallium and tended to show fewer artifacts due to
soft tissue attenuation. Better definition of the myocardium, en-
docardial and epicardial borders, and perfusion defects has been
observed. In general, there was much less statistical noise using
these Tc-99m labeled tracers and the myocardial to background
ratios were similar to those obtained with thallium imaging. More-
over, the permissible administered dose is much larger than for
thallium. It resulted in an increase in pixel count densities for Tc-
99m labeled tomographic projection images and it permits the
use of higher resolution filters during studies reconstruction. Nu-
clear cardiology imaging techniques as well as the development
of Tc-99m labeled perfusion tracers now permits combined myo-
cardial-perfusion and LV function studies at a single testing inter-
val. Thus, the potential advantages of simultaneous assessment
of myocardial perfusion ad LV function have been recently out-
lined [4]. Gated imaging of the perfused myocardium is a well-
established technique for this purpose, with a single injection of
a Tc-99m labeled perfusion tracer. Recent data have demonstrat-
ed the impact and clinical role of these studies in the diagnosis of
patients with suspected or known coronary artery disease. The
addition of functional information to perfusion data has shown to
improve the detection of multivessel disease.
Prognosis in patients with coronary artery
disease
Another key role of myocardial perfusion imaging has been its
ability to provide prognostic information in patients after acute
myocardial infarction, in patients with chronic coronary artery dis-
ease and in patients scheduled for major surgery [5]. The utility of
thallium scintigraphy associated with exercise pharmacological
stress testing for this purpose has been widely documented. In
particular, it has been demonstrated that in patients without prior
myocardial infarction the number of reversible thallium defects is
the most important statistically significant predictor of future car-
diac events. Moreover, the extent and severity of thallium defects
correlate with the occurrence of cardiac event. Several studies
have reported similar results on the prognostic value of thallium
stress imaging after myocardial infarction and in patients with sus-
pected or known coronary artery disease. These data demonstrat-
ed that the extent of perfusion abnormality on SPECT imaging is
the single most important prognostic predictor. More recently, the
prognostic value of Tc-99m labeled myocardial perfusion agents
has been demonstrated with concordant data as compared to
thallium imaging. In particular, the extent of hypoperfusion on post-
stress sestamibi images can be factored into a decision-making
process relative to selecting medical therapy or revascularization.
Patients with mild reversible perfusion defects judged to be not at
high risk could most often be treated medically whereas patients
with high-risk SPECT reversibility findings are candidates for fur-
ther invasive strategies. Moreover, a strategy incorporating stress
myocardial perfusion imaging is also cost-effective. A large study
comprising stable angina patients referred for stress myocardial
perfusion SPECT imaging or direct catheterization revealed that
costs were higher for the initial invasive strategy in clinical subsets
with low, intermediate or high pretest likelihood of disease. Diag-
nostic follow-up costs of care were 30% to 41% higher for patients
undergoing direct catheterization without any reduction in mortal-
ity or infarction compared with patients having stress perfusion
imaging as the initial test for coronary artery disease detection.
Myocardial viability
It has been demonstrated that one-third of patients with chronic
coronary artery disease and LV dysfunction have the potential for
significant improvement in ventricular function after myocardial
revascularization procedures. These findings have several impli-
cations. First, given the important relationship between LV func-
tion and patients survival. During the past years, numerous stud-
ies have demonstrated that nuclear cardiology techniques involv-
ing SPECT provide important viability information in patients with
coronary artery disease and impaired ventricular function [6–12].
Although positron emission tomography (PET) remains the most
accurate technique for the detection of viable myocardium differ-
ent thallium protocols have been used in previous studies to as-
sess myocardial viability in patients with previous myocardial inf-
arction and chronic LV dysfunction. In particular, if the clinical is-
sue to be addresses is the viability of one or more ventricular re-
gions with systolic dysfunction and not whether there is also in-
ducible ischemia, rest-redistribution thallium imaging can yield
useful viability data. In particular, it has been demonstrated that
quantitative analysis of rest-redistribution images predicts recov-
ery of regional LV function and compares favorably to the results
of both thallium reinjection imaging and metabolic PET imaging [7].
Optimal interpretation of thallium imaging for the detection of
myocardial viability can be accomplished by measuring regional
tracer uptake and by selecting the most appropriate cutoff to dif-
ferentiate reversible from irreversible LV dysfunction [8–10]. Fur-
thermore, sestamibi and tetrofosmin showed similar results to
those of thallium scintigraphy in the identification of viable myo-
cardium [8]. A quantitative analysis of tracers’ content as well as
the administration of nitroglycerin prior to tracer injection increas-
es the overall accuracy of Tc-99m labeled agents for identifying
viable myocardium. Recent data indicated that in patients with chron-
ic myocardial infarction and impaired LV function on nitrate treat-
ment, quantitative analysis of resting thallium and sestamibi regional
activities comparably predicts recovery of regional and global ven-
tricular function following revascularization procedures [11]. Nitro-
glycerin most likely enhances myocardial viability detection by in-
creasing coronary collateral flow, decreasing pre-load and after-
load, and direct vasodilatation of stenotic segments in coronary
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arteries [12–14]. These physiological effects in combination should
enhance the delivery of myocardial perfusion agents to regions of
myocardium supplied by severely stenotic vessels. In the assess-
ment of myocardial viability myocardial perfusion in combination
with wall motion analysis by gated images has been used [15].
Despite the recovery of regional function after revascularization
was the more considered gold standard to detect myocardial via-
bility, the clinical outcome after revascularization is a better and
more valuable end-point. The criteria for viability determination
with respect to its true clinical impact should be the prediction of
short- and long-term outcomes such as cardiovascular mortality
and recurrent myocardial infarction [16]. It should be considered
that preserved myocardial perfusion tracer uptake in zones of asyn-
ergy might have a sub-optimal positive predictive value for pre-
dicting improved segmental function after revascularization. How-
ever, it appears to predict a high cardiac death and infarction rate
with medical therapy and identifies a group of patients with hiber-
nating myocardium who would be predicted to have an excellent
outcome after revascularization. Has been demonstrated that the
amount of dysfunctional myocardium with preserved thallium up-
take provided independent prognostic information that were in-
cremental to those obtained by clinical, functional, and angiograph-
ic data in patients with chronic ischemic LV dysfunction. In partic-
ular, patients with a substantial amount (> 30% of the total left
ventricle) of dysfunctional myocardium with preserved tracer ac-
tivity exhibited the greatest LV functional benefit after successful
revascularization [17]. Moreover, patients with more than 50% of
viable myocardium represented a subgroup at high-risk of cardi-
ac death in whom successful revascularization improved survival
[17]. All together these observations seem to lend further support
to the choice of coronary revascularization in patients with evi-
dence of a substantial amount of dysfunctional myocardium with
preserved myocardial perfusion tracer activity. Thus, it appears
that the assessment of myocardial viability should became a man-
datory step in the clinical decision-making of patients with reduced
global and regional LV systolic function to better predict the po-
tential value of revascularization in improving survival and func-
tional status.
Evaluation after coronary revascularization
The use of exercise or pharmacological myocardial perfusion
imaging in the assessment of interventions in chronic ischemic
heart disease is indicated for the evaluation of restenosis after
percutaneous transluminal coronary angioplasty (PTCA) in symp-
tomatic patients, in the assessment of ischemia in symptomatic
patients after coronary artery bypass grafting (CABG). Radionu-
clide techniques are also indicated in the assessment of selected
asymptomatic patients after PTCA or CABG, such as patients with
an abnormal electrocardiographic response to exercise or those
with rest electrocardiographic changes precluding identification
of ischemia during exercise. SPECT exercise imaging is an excel-
lent tool for the detection of restenosis and disease progression
after PTCA in the settings of one and multivessel angioplasty and
complete and partial revascularization. Hecht et al. [18], studying
exercise tomographic thallium imaging in the detection of rest-
enosis after PTCA, showed sensitivity of 93% for scintigraphic stud-
ies and 52% for exercise electrocardiographic studies, specificity
of 77% versus 64% and accuracy of 86% versus 57%, respective-
ly. Moreover, it has been demonstrated that after PTCA sensitivity
and accuracy of exercise electrocardiography in the detection of
restenosis were significantly less than those of SPECT imaging
for both patients with silent and symptomatic ischemia [19]. Pa-
tients with less typical symptoms and intermediate probability of
restenosis can be accurately assessed for this PTCA complica-
tion by myocardial perfusion imaging studies. In the patients with
recurrent atypical symptoms, stress perfusion imaging should be
performed soon after the onset of symptoms in order to deter-
mine whether persistent myocardial ischemia is the cause of chest
pain. Myocardial imaging studies offer several advantages over
stress electrocardiography, particularly in patients with abnormal-
ities of the resting electrocardiogram, multivessel coronary dis-
ease, or a limitation to exercise stress testing. After PTCA nuclear
cardiac imaging procedures are not generally recommended in
the absence of recurrent symptoms, particularly since imaging
abnormalities would not likely result in change in therapeutic reg-
imen or repeat revascularization. However, recent data demon-
strated that extent and severity of myocardial ischemia at exercise
SPECT performed between 12 and 18 months after percutaneous
coronary intervention (PCI) predicts cardiac events during long-term
follow-up in symptomatic and symptom-free patients [20].
Exercise scintigraphy after CABG demonstrates improved re-
gional myocardial perfusion in most patients. After CABG, the New
York Heart Association’s functional class improved significantly.
Early (less than 3 month) post-CABG myocardial imaging may be
useful for the detection of perioperative infarction or if early graft
closure with recurrence of angina symptoms is suspected. Be-
yond 3 months, and following the recovery of hibernation effects,
noninvasive cardiac imaging is useful to detect asymptomatic graft
attrition and the recurrence of myocardial ischemia. However, this
approach cannot be routinely recommended in all patients who
underwent CABG because it would not be cost-effective to screen
this large population in the 1 to 2 years following CABG surgery.
PET imaging in cardiology
PET imaging has been shown to be a method for the detec-
tion and characterization of coronary artery disease showing su-
perior results as compared to SPECT imaging. The experimental
and clinical experience with metabolic imaging led to the devel-
opment of 18F-fluorodeoxyglucose (FDG) as a marker of tissue
viability in patients with advanced coronary artery disease. Based
on these studies, PET became an accepted clinical tool for the
detection of coronary artery disease as well as assessment of
tissue viability. PET imaging has been validated also for the non-
invasive characterization of coronary artery disease and other
cardiovascular disorders. In particular, to describe the interaction
of various substrates for cardiac energy metabolism.
One of the applications of PET for the detection of coronary
artery disease is the assessment of regional myocardial tracer
distribution under rest and stress conditions. Most commonly,
pharmacological stress testing has been employed in order to
assess coronary reserve. The quantification of coronary flow re-
serve has been advocated for the functional assessment of the
severity of coronary artery stenosis in patients with coronary ar-
tery disease. The parameter flow reserve integrates the functional
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significance of a given coronary lesion, vascular reactivity and
collateral blood flow in the post-stenotic vascular territories. It has
been hypothesized that such functional measurements may com-
plement the anatomic description of coronary artery disease and
may helpful in the selection of patients for revascularization. Add-
ing functional information to an angiographic description of coro-
nary artery disease increases objectivity in the evaluation of dis-
ease severity and provides a noninvasive means to follow pro-
gression and regression of coronary artery disease [21, 22]. PET
imaging with N-13 ammonia and O-15 water has been used for
the evaluation of coronary flow reserve in normal heart, in patients
with coronary artery disease and non coronary artery disease.
Assessment of relative coronary reserve by PET imaging relies on
the hypothesis that at least one segment of the myocardium dis-
plays a normal coronary reserve. This segments serves as an in-
ternal standard to which all other segments are normalized. How-
ever, this may not be possible in patients with severe triple-vessel
disease or other diseases affecting coronary reserve measure-
ments. It has been demonstrated a relationship between coro-
nary reserve measurements and age in subjects without coronary
artery disease. Moreover, considering hemodynamic parameters
such as blood pressure and heart rate, the decreased coronary
reserve values in elderly persons may be primarily due to increased
resting blood flow as a consequence of higher heart rate and blood
pressure in elderly population. Clinical data have indicated that
arterial hypertension leads to reduced coronary flow reserve. It
has been shown using PET that therapy of patients with arterial
hypertension may improve regional coronary reserve measure-
ments. In patients with coronary artery disease coronary flow re-
serve measurements are reduced. Several studies indicated
a correlation between the severity of coronary artery disease and
severity of flow reserve impairment. However, in the range of in-
termediate coronary artery stenosis more discrepancies between
angiographic and PET results are present. It may be best explained
considering different aspects such as the complex geometric
shape of atherosclerotic plaques that may be difficult to judge
from angiographic views. Moreover, collateral blood flow may al-
ter the relationship of coronary stenosis and blood flow measure-
ments to the stenosis site. All these factors emphasize the impor-
tance of blood flow measurements to document the functional
severity of a given angiographic lesion. Quantitative flow mea-
surements with PET have been employed in patients with cardiac
transplantation to study coronary physiology and in patients with
cardiomyopathy. Due to the improved image technology, PET
perfusion imaging has been shown to be a superior method for
the detection and the characterization of coronary artery disease
as compared to SPECT. Thus, noninvasive detection of coronary
artery disease by PET allows better definition of the functional
importance of known coronary artery stenosis. Clinic data com-
bining the results of different studies in about 300 patients sug-
gest that PET imaging improve the diagnostic accuracy of SPECT
by about 10%. However, the relative higher cost of PET as com-
pared to SPECT and lesser availability of the former should be
considered when selecting the imaging technique. Therefore, al-
though PET is an effective modality for noninvasive diagnosis of
coronary artery disease it should be considered for routine diag-
nostic purposes only if its costs are equivalent or less than those
of SPECT imaging in the same environment.
The scintigraphic methods for evaluation of myocardial viabil-
ity could be broadly categorized into SPECT with agents assess-
ing both perfusion and metabolic activity, and PET with tracers
assessing coronary blood flow and metabolic activity, including
evaluation of both fatty acid and glucose metabolism. Although
quantitative approaches to viability assessment using SPECT and
standard tracers may provide valuable information with regard to
myocardial viability, PET offers different advantages. An accurate
quantification of tracer distribution after correction for attenuation,
enhanced spatial resolution and the possibility to use tracers that
are specifically targeted at defining a certain metabolic parameter
(e.g. glucose utilization or oxidative metabolism). Given the tech-
nical superiority of PET over SPECT, PET would appear to be the
preferred technique to assess both perfusion and metabolism in
patients with chronic coronary artery disease and left ventricular
dysfunction. However, by serving as a reference standard, PET
has played an important role in recent modifications and improve-
ments of SPECT technology and protocols. In particular, more
recently it has been suggested that F-18 FDG SPECT can be used
as alternative to PET and SPECT with perfusion tracers for the
assessment of viability. In fact, the availability and high cost of
PET and cyclotron technology have limited the clinical application
of this technique. Moreover, because of the relatively long physi-
cal half-life of F-18 (110 min), off-site production of labeled FDG
and subsequent transport to satellite laboratories have been pro-
posed. This, combined with the advent of high-energy gamma
camera collimators, has made possible the use of FDG SPECT
for detection of myocardial viability. However, although FDG
SPECT significantly increases the sensitivity for detection of via-
ble myocardium in tissue declared nonviable by thallium (to 88%
of the sensitivity achievable by PET), it will occasionally (27% of
the time) result in falsely identifying as viable tissue that has been
identified as nonviable by both PET and thallium [23]. Clinical stud-
ies have been performed comparing fatty acid and glucose me-
tabolism in relation to functional recovery of ischemic myocardi-
um after coronary revascularization. Bax et al. [24] suggested that
tomographic metabolic imaging with FDG may be useful in the
prediction of improvement of LV function after revascularization in
patients with coronary artery disease. In a recent study by Sato
et al. [25] it has been demonstrated that combined metabolic
SPECT imaging with FDG and iodine-123 (I-123) labeled methyl-
iodophenil-pentadecanoic acid (BMIPP) have the potential to
identify severely impaired ischemic myocardium leading to more
efficient therapeutic management of patients with coronary ar-
tery disease. In fact, areas with discordant BMIPP uptake less
than thallium are often seen in patients with coronary artery dis-
ease, which may represent ischemic but viable myocardium
where increased glucose metabolism was also observed. Fur-
ther information regarding functional recovery in patients stud-
ied with FDG SPECT imaging is needed to confirm this point
and to define the relationship between FDG uptake on SPECT
imaging and functional outcome.
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